FEUGIER , Pierre

Last name: FEUGIER

First name: Pierre

2014 (v1)

Journal article

Metadata-only

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia

Cornet, Edouard Delmer, Alain Feugier, Pierre

Hairy cell leukaemia (HCL) is a rare haematological malignancy, with approximately 175 new incident cases in France. Diagnosis is based on a careful examination of the blood smear and immunophenotyping of the tumour cells, with a panel of four markers being used specifically to screen for hairy cells (CD11c, CD25, CD103 and CD123). In 2011, the...

Uploaded on: March 26, 2023
December 7, 2019 (v1)

Publication

Metadata-only

Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study)

Bohers, Elodie Viailly, Pierre-Julien Ruminy, Philippe

IntroductionThe outcome of very elderly patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) remains poorer than that of younger patients, often because of co-morbidities and physiological organ function impairment. However, the biological specificities of DLBCL in very elderly patients are unknown. The LYSA conducted a...

Uploaded on: December 4, 2022
2021 (v1)

Journal article

Metadata-only

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

Oberic, Lucie Peyrade, Frédéric Puyade, Mathieu

PURPOSE: The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of young patients. An attenuated dose of chemotherapy-cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-miniCHOP)-is a good compromise between efficacy and safety in very elderly patients. In combination with...

Uploaded on: December 4, 2022

FEUGIER , Pierre

Recent uploads